Focal Cerebral Vasculitis due to SARS-CoV-2 Infection With a Robust Response to Intravenous Steroids.
Journal
The neurologist
ISSN: 2331-2637
Titre abrégé: Neurologist
Pays: United States
ID NLM: 9503763
Informations de publication
Date de publication:
23 Aug 2023
23 Aug 2023
Historique:
medline:
24
8
2023
pubmed:
24
8
2023
entrez:
23
8
2023
Statut:
aheadofprint
Résumé
Severe and less common neurological manifestations of SARS-CoV-2 infection include acute ischemic stroke, intracerebral hemorrhage, central venous sinus thrombosis, and vasculitis. In this report, we present a case of a 42-year-old man with acute ischemic stroke due to SARS-CoV-2 infection-associated central nervous system vasculitis that improved with steroid therapy. A 42-year-old man with SARS-CoV-2 infection presented with non-fluent aphasia and right-sided hemiparesis. Computed tomography angiography revealed an occlusion of the proximal left middle cerebral artery (MCA), with acute infarcts in the left posterior parietal, lentiform nucleus, and cortical frontal cortex on magnetic resonance imaging (MRI). Patient developed pulmonary emboli and was discharged on apixaban and atorvastatin. Four weeks later, the patient presented with recurring symptoms and was found to have worsening left MCA stenosis. MRI and MR angiography revealed a penumbra within the left MCA territory and pruning of the distal branches with severe stenosis. Laboratory workup for autoimmune causes of vasculitis was unrevealing. High-dose intravenous steroid treatment was initiated. Subsequent MRI and MR angiography revealed improved flow in the left cerebral vasculature and no novel ischemic infarcts. Central nervous system vasculitis is a rare manifestation of SARS-CoV-2 infection. This case suggests that high-dose intravenous steroids may have a therapeutic role in this patient population. Steroid use, in combination with vasopressor support to augment cerebral blood flow, may prevent further stroke burden.
Identifiants
pubmed: 37611403
doi: 10.1097/NRL.0000000000000525
pii: 00127893-990000000-00094
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Chua AMU, Jamora RDG, Jose ACE, et al. Cerebral vasculitis in a COVID-19 confirmed postpartum patient: a case report. Case Reports in Neurology. 2021. Accessed July 12, 2022. https://www.karger.com/Article/FullText/515815#
Hanafi R, Roger PA, Perin B, et al. COVID-19 neurologic complication with CNS vasculitis-like pattern. AJNR Am J Neuroradiol. 2020;41:1384–1387.
Vaschetto R, Cena T, Sainaghi PP, et al. Cerebral nervous system vasculitis in a Covid-19 patient with pneumonia. J Clin Neurosci. 2020;79:71–73.
Poisson KE, Zygmunt A, Leino D, et al. Lethal pediatric cerebral vasculitis triggered by Severe Acute Respiratory Syndrome Coronavirus 2. Pediatr Neurol. 2022;127:1–5.
Timmons GM, Rempe T, Bevins EA, et al. CNS lymphocytic vasculitis in a young woman with COVID-19 infection. Neurol Neuroimmunol Neuroinflamm. 2021;8:e1048–e1051.
Lersy F, Kremer S. Meningeal inflammation and cerebral vasculitis during acute COVID-19 with spontaneous regression. Intensive Care Med. 2022;48:233–235.
Sharifian-Dorche M, Huot P, Osherov M, et al. Neurological complications of coronavirus infection; a comparative review and lessons learned during the COVID-19 pandemic. J Neurol Sci. 2020;417:117085.
Lersy F, Anheim M, Willaume T, et al. Cerebral vasculitis of medium-sized vessels as a possible mechanism of brain damage in COVID-19 patients. J Neuroradiol. 2021;48:141–146.
Monteil V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181:905–913.e7.